metastatic colorectal cancer

$Enhancing Quality of Life in KRASG12C-Mutated Chemorefractory Metastatic Colorectal Cancer: Insights from the CodeBreaK 300 Phase 3 Trial$

Clinical Updates Wellness & Lifestyle

Enhancing Quality of Life in KRASG12C-Mutated Chemorefractory Metastatic Colorectal Cancer: Insights from the CodeBreaK 300 Phase 3 Trial

By MedXY 09/21/2025

The phase 3 CodeBreaK 300 trial shows sotorasib plus panitumumab improves health-related quality of life and clinical outcomes in KRASG12C-mutated metastatic colorectal cancer compared to standard care.

Clinical Updates Wellness & Lifestyle

Early ctDNA Dynamics Predict Long-Term Survival in dMMR/MSI-H Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors

By MedXY 09/13/2025

Change in circulating tumor DNA (ctDNA) one month after treatment initiation predicts progression-free and overall survival in patients with dMMR/MSI-H metastatic colorectal cancer receiving immune checkpoint inhibitors, offering a potential biomarker for therapeutic decision-making.

Clinical Updates Wellness & Lifestyle

Prognostic Role of HER2 Amplification and Mutations in Metastatic Colorectal Cancer: Insights from Eight Randomized Trials

By MedXY 09/10/2025

HER2 amplification/mutation in RAS/BRAF wild-type metastatic colorectal cancer is a negative prognostic factor but does not predict differential benefit from bevacizumab or anti-EGFR therapies, based on analysis of 1,604 patients across eight randomized trials.

Clinical Updates Wellness & Lifestyle

Early ctDNA Variation as a Prognostic Biomarker in dMMR/MSI-H Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors: Insights from the SAMCO-PRODIGE 54 Trial

By MedXY 08/23/2025

A secondary analysis of the SAMCO-PRODIGE 54 trial reveals that early changes in circulating tumor DNA predict long-term outcomes in dMMR/MSI-H metastatic colorectal cancer patients treated with immune checkpoint inhibitors.

Clinical Updates Wellness & Lifestyle

First-Line Encorafenib, Cetuximab, and mFOLFOX6 in BRAF V600E–Mutated Metastatic Colorectal Cancer: Clinical Impact from the BREAKWATER Trial

By MedXY 08/01/2025

Combination therapy with encorafenib, cetuximab, and mFOLFOX6 significantly improves progression-free and overall survival compared to standard care in first-line treatment of BRAF V600E–mutated metastatic colorectal cancer.